Sarah R Leist

List of Publications by Year
in descending order

46 papers	11,633 citations	159358 30 h-index	233125 45 g-index
62 all docs	62 docs citations	62 times ranked	20406 citing authors

#	Article	IF	Citations
1	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 2020, 11, 222.	5.8	1,376
2	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 2017, 9, .	5.8	1,279
3	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 2020, 182, 429-446.e14.	13.5	1,257
4	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
5	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science Translational Medicine, 2020, 12, .	5.8	886
6	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468.	6.0	808
7	Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio, 2018, 9, .	1.8	557
8	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020, 586, 560-566.	13.7	527
9	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 2020, 183, 1070-1085.e12.	13.5	472
10	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	13.5	420
11	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Reports, 2020, 32, 107940.	2.9	412
12	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, 591, 451-457.	13.7	320
13	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	4.2	283
14	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science, 2021, 373, 991-998.	6.0	144
15	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
16	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26915-26925.	3.3	104
17	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell, 2020, 183, 429-441.e16.	13.5	100
18	Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. MSphere, 2017, 2, .	1.3	92

#	Article	IF	Citations
19	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29832-29838.	3.3	81
20	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	2.7	77
21	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	2.9	64
22	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	2.1	61
23	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
24	Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. Journal of Virology, 2018, 92, .	1.5	58
25	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
26	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathogens, 2021, 17, e1009897.	2.1	49
27	Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice. BMC Genomics, 2016, 17, 143.	1.2	48
28	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	46
29	In vivo knockdown of Piccolino disrupts presynaptic ribbon morphology in mouse photoreceptor synapses. Frontiers in Cellular Neuroscience, 2014, 8, 259.	1.8	44
30	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Reports, 2021, 36, 109450.	2.9	38
31	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2â€"specific monoclonal antibody CR3022. JCI Insight, 2021, 6, .	2.3	34
32	Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. Cell Reports, 2020, 31, 107587.	2.9	31
33	Giving the Genes a Shuffle: Using Natural Variation to Understand Host Genetic Contributions to Viral Infections. Trends in Genetics, 2018, 34, 777-789.	2.9	29
34	Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis. Journal of General Virology, 2019, 100, 1073-1078.	1.3	26
35	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathogens, 2021, 17, e1009287.	2.1	22
36	Of mice and men: the host response to influenza virus infection. Mammalian Genome, 2018, 29, 446-470.	1.0	19

#	Article	IF	Citations
37	Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. Mammalian Genome, 2018, 29, 367-383.	1.0	17
38	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. SSRN Electronic Journal, 0, , .	0.4	15
39	Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. PLoS ONE, 2019, 14, e0220126.	1.1	13
40	H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice. Virology Journal, 2020, 17, 56.	1.4	13
41	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	1.5	12
42	Genetically Engineering a Susceptible Mouse Model for MERS-CoV-Induced Acute Respiratory Distress Syndrome. Methods in Molecular Biology, 2020, 2099, 137-159.	0.4	11
43	A Multitrait Locus Regulates Sarbecovirus Pathogenesis. MBio, 2022, 13, .	1.8	11
44	ExÂvivo and inÂvivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. Molecular Therapy, 2022, 30, 2005-2023.	3.7	10
45	Lst1 deficiency has a minor impact on course and outcome of the host response to influenza A H1N1 infections in mice. Virology Journal, 2016, 13, 17.	1.4	5
46	Therapeutic Potential of SARS-CoV-2-Specific Monoclonal Antibody CR3022. SSRN Electronic Journal, 0, , .	0.4	1